Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production
Northwest Biotherapeutics believes NHSBT's capabilities can enhance DCVax-L scale-up and accessibility.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Northwest Biotherapeutics (NWBO) has entered a collaboration with NHS Blood and Transplant to support UK production of experimental cancer vaccine DCVax-L. The work involves Advent Bioservices and initially covers Leeds and Oxford.
NHSBT's Therapeutic Apheresis Services teams collect the immune-cell starting material through leukapheresis, a procedure that separates specific white blood cells and returns the remaining blood components to the patient. Its Cellular and Molecular Therapies teams provide cell processing and handling for the next stages of personalized manufacturing.
The organizations are exploring phased expansion to additional NHSBT locations across England and broader collaboration using NHSBT's specialist laboratory and advanced-therapy capabilities. These additional activities remain exploratory.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointNHSBT collaboration supports UK DCVax-L production through immune-cell collection and specialist cell processing.
- Minor point. Forward-looking: it has not happened yet and may not happen.Phased expansion to additional NHSBT locations across England is being explored with Advent Bioservices.
- Minor point. Forward-looking: it has not happened yet and may not happen.Broader collaboration involving NHSBT's specialist laboratory and advanced-therapy capabilities is also being explored.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The NHSBT announcement can be found at https://lnkd.in/p/eVd5u-Yr and states as follows:
NHS Blood and Transplant's specialist therapeutic apheresis and cell processing capabilities are supporting the production of DCVax®-L, with plans to expand the model to additional locations across
NHS Blood and Transplant's Therapeutic Apheresis Services (TAS) and Cellular and Molecular Therapies (CMT) teams are supporting the
Working in collaboration with Northwest Biotherapeutics and Advent Bioservices, NHSBT's specialist teams are supporting key stages of the manufacturing: TAS is carrying out leukapheresis procedures to collect the immune cell starting material needed for the DCVax®-L treatment, forming part of the personalised manufacturing process for an individual patient. Leukapheresis is an established procedure in which blood is collected and separated so that specific white blood cells can be obtained, while the remaining blood components are returned to the patient.
CMT is providing specialist cell processing and handling of cellular material to support the onward pathway.
The collaboration between NHSBT and Northwest Biotherapeutics brings together this clinical and operational expertise with the work of NWBio and Advent Bioservices in developing DCVax®-L in the
The collaboration initially involves
Ms. Linda Powers, CEO of Northwest Biotherapeutics, said:
"NHSBT's impressive expertise and facilities for advanced therapies are at the forefront of the field. We are very excited about collaborating with them on our DCVax®-L personalised immune therapies for cancer. We believe NHSBT's capabilities can significantly enhance the scale-up and accessibility of DCVax®-L."
Dr James Griffin, Medical Director at NHSBT, said:
"The collaboration forms part of ongoing work between NHSBT, NWBio and Advent Bioservices to strengthen the infrastructure supporting the production of DCVax®-L in the
About the
NHSBT provides specialist Therapeutic Apheresis Services through units in
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program involves DCVax®-L treatment for glioblastoma (GBM). GBM is the most aggressive and lethal form of primary brain cancer, and is an "orphan disease." The Company has completed a 331-patient Phase III trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and plans to pursue Phase II trials this year. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning plans for DCVax® are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those projected in any forward-looking statement. Readers should not rely upon forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those anticipated, including, without limitation, risks related to delays or uncertainties in regulatory processes and decisions, risks related to the Company's ability to achieve timely performance of third parties, risks related to whether the Company's products will be viewed as demonstrating safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual plans, results or timelines to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
CONTACTS
Northwest Biotherapeutics
Dave Innes
804-513-4758
dinnes@nwbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-the-uk-national-health-service-blood-and-transplant-announce-collaboration-to-support-dcvax-l-production-302903002.html
SOURCE Northwest Biotherapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Northwest Biotherapeutics' NHSBT collaboration involve for DCVax-L production?
NHSBT supports DCVax-L production by collecting immune-cell starting material and providing specialist cell processing and handling. The collaboration involves Northwest Biotherapeutics and Advent Bioservices, with NHSBT teams supporting stages of the personalized manufacturing process.
Where is Northwest Biotherapeutics' DCVax-L collaboration with NHSBT starting?
The collaboration initially involves Leeds and Oxford. NHSBT, Northwest Biotherapeutics and Advent Bioservices are exploring phased expansion to additional NHSBT locations across England.